Sepsis diagnostics market outlook (2026–2030) driven by growth factors

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Sepsis Diagnostics Market Expected To Reach Based On Its 2026 Value?

The sepsis diagnostics market has experienced substantial expansion in recent years. It is anticipated to grow from $1.07 billion in 2025 to $1.16 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.3%. During the historical period, this growth was primarily driven by the increase in hospital-acquired infections, the adoption of rapid diagnostic tests, various regulatory approvals, improvements in lab infrastructure, and a rise in clinical awareness.

The sepsis diagnostics market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $1.57 billion by 2030, achieving a compound annual growth rate (CAGR) of 7.9%. This expansion during the forecast period is fueled by elements such as AI-enabled diagnostic platforms, a rise in biomarker-based testing, tele-diagnostic integration, new sepsis detection assays, and the advancement of point-of-care diagnostics. Noteworthy trends for the forecast period comprise point-of-care diagnostic devices, biomarker-based tests, rapid blood culture kits, AI-assisted diagnostic platforms, and their integration with hospital IT systems.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23514&type=smp

Which Key Factors Are Driving The Sepsis Diagnostics Market Growth?

An increasing occurrence of hospital-acquired infections is anticipated to boost the expansion of the sepsis diagnostics market in the future. Hospital-acquired infections (HAIs) are defined as infections emerging either during a patient’s hospitalization or subsequent to their discharge, generally occurring 48 hours or more post-admission, and absent upon initial admission. The growing prevalence of hospital-acquired infections stems from an uptick in antibiotic resistance. The excessive and inappropriate use of antibiotics within healthcare environments has fostered the emergence of resistant bacteria, complicating infection treatment. Early detection of hospital-acquired infections is facilitated by sepsis diagnostics, which pinpoints pathogens and biomarkers, allowing for prompt intervention and minimizing adverse outcomes. As an illustration, in November 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that for 2022–23, healthcare-associated complications (HACs) were identified in 2% of public hospital admissions and 0.8% of private hospital admissions, with healthcare-associated infections constituting the most common complication. Consequently, the escalating rate of hospital-acquired infections is a primary driver for the growth within the sepsis diagnostics market.

How Is The Sepsis Diagnostics Market Categorized Across Its Segment Groups?

The sepsis diagnostics market covered in this report is segmented –

1) By Product: Instruments, Blood Culture Media, Assay Kits And Reagents, Software

2) By Technology: Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry, Other Technologies

3) By Pathogen: Bacterial Sepsis, Fungal Sepsis, Viral Sepsis, Other Pathogens

4) By Method: Automated Diagnostics, Conventional Diagnostics

5) By End-Users: Hospitals And Clinics, Pathology And Reference Laboratories, Research Institutes

Subsegments:

1) By Instruments: Automated Analyzers, Point-Of-Care (PoC) Testing Devices, Microfluidic-Based Devices, Polymerase Chain Reaction (PCR) Instruments, Flow Cytometers

2) By Blood Culture Media: Aerobic Blood Culture Media, Anaerobic Blood Culture Media, Mycobacteria Blood Culture Media, Pediatric Blood Culture Media, Fungal Blood Culture Media

3) By Assay Kits And Reagents: Enzyme-Linked Immunosorbent Assay (ELISA) Kits, Polymerase Chain Reaction (PCR) Assay Kits, Immunoassay Reagents, Molecular Diagnostic Reagents, Biosensor-Based Assay Kits

4) By Software: Data Management Software, Laboratory Information Systems (LIS), Artificial Intelligence (AI)-Based Diagnostic Tools, Predictive Analytics Software, Cloud-Based Diagnostic Platforms

Which Trends Are Guiding The Direction Of The Sepsis Diagnostics Market?

Leading companies in the sepsis diagnostics market are concentrating on creating innovative solutions, such as culture-free diagnostic methods, to facilitate swift and precise identification of sepsis without relying on conventional blood cultures. A culture-free diagnostic solution offers a way to detect pathogens or infections without the necessity of traditional microbial culturing techniques. These solutions leverage advanced technologies like polymerase chain reaction (PCR), next-generation sequencing (NGS), or immunoassays to quickly pinpoint pathogens directly from patient samples such as blood, saliva, or tissue. For instance, in April 2024, Deepull Diagnostics S.L., a manufacturing firm based in Spain, introduced the UllCORE diagnostic system for the early detection of sepsis. The UllCORE system is a benchtop, culture-free multiplex PCR platform developed by Deepull for the rapid identification of pathogens in sepsis and other acute infections. It extracts microbial DNA from 8 mL of whole blood and delivers 50 reportable results within one hour. The system identifies 95% of pathogens responsible for sepsis, including bacteria, fungi, and antibiotic resistance genes. Designed to enhance early diagnosis and reduce inappropriate antibiotic use, UllCORE aids hospitals in their fight against antimicrobial resistance.

Which Firms Are Influencing Competition In The Sepsis Diagnostics Market?

Major companies operating in the sepsis diagnostics market are Siemens Healthcare GmbH, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Koninklijke Philips N.V., GE Healthcare, Wolters Kluwer N.V., bioMérieux S.A., Bruker Corporation, DiaSorin S.p.A., Cepheid Inc., Seegene Inc., Luminex Corporation, T2 Biosystems Inc., Cytovale Inc., Accelerate Diagnostics Inc., Immunexpress Inc., EKF Diagnostics Holdings plc, Boditech Med Inc., Alifax S.r.l., Abionic SA

Get The Full Sepsis Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/sepsis-diagnostics-global-market-report

Where Is The Sepsis Diagnostics Market Primarily Concentrated By Region?

North America was the largest region in the sepsis diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sepsis diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Sepsis Diagnostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/sepsis-diagnostics-global-market-report

Browse Through More Reports Similar to the Global Sepsis Diagnostics Market 2026, By The Business Research Company

Hospital Acquired Infection Control Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infection-control-global-market-report

Hemophilia Market Report

https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Clinical Microbiology Market Report

https://www.thebusinessresearchcompany.com/report/clinical-microbiology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795